Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ADP + adenosine
2 AMP
47.7% conversion
-
-
?
ATP + 2'-amino-2',3'-dideoxyadenosine
ADP + 2'-amino-2',3'-dideoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxy-2,2'-difluoro-adenosine
ADP + 2'-deoxy-2,2'-difluoro-AMP
ATP + 2'-deoxy-adenosine
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
ATP + 2,3-difluoro-3-deaza-7-iso-adenosine
ADP + 2,3-difluoro-3-deaza-7-iso-AMP
ATP + 2,3-difluoro-3-deaza-7-isoadenosine
ADP + 2,3-difluoro-3-deaza-7-isoadenosine 5'-phosphate
ATP + 2,3-difluoro-3-deaza-adenosine
ADP + 2,3-difluoro-3-deaza-AMP
ATP + 2,3-difluoro-3-deazaadenosine
ADP + 2,3-difluoro-3-deazaadenosine 5'-phosphate
ATP + 2,6-diaminopurine riboside
ADP + 2,6-diaminopurine riboside 5'-phosphate
-
-
-
-
?
ATP + 2-(4-benzylpiperazin-1-yl)adenosine
ADP + 2-(4-benzylpiperazin-1-yl)adenosine 5'-phosphate
-
3% of the activity with adenosine
-
-
?
ATP + 2-(pyrrolidin-1-yl)adenosine
ADP + 2-(pyrrolidin-1-yl)adenosine 5'-phosphate
-
53% of the activity with adenosine
-
-
?
ATP + 2-amino-carbocyclic-adenosine
?
-
35.8% of the activity with adenosine
-
-
?
ATP + 2-amino-carbocyclic-adenosine
ADP + 2-amino-carbocyclic-AMP
ATP + 2-azaadenosine
ADP + 2-azaadenosine 5'-phosphate
ATP + 2-benzylaminoadenosine
ADP + 2-benzylaminoadenosine 5'-phosphate
-
4% of the activity with adenosine
-
-
?
ATP + 2-chloro-adenosine
?
-
0.7% of the activity with adenosine
-
-
?
ATP + 2-chloro-adenosine
ADP + 2-chloro-AMP
ATP + 2-chloroadenosine
ADP + 2-chloroadenosine 5'-phosphate
ATP + 2-cyclohexylaminoadenosine
ADP + 2-cyclohexylaminoadenosine 5'-phosphate
-
3% of the activity with adenosine
-
-
?
ATP + 2-ethylaminoadenosine
ADP + 2-ethylaminoadenosine 5'-phosphate
-
3% of the activity with adenosine
-
-
?
ATP + 2-fluoro-3-deaza-adenosine
ADP + 2-fluoro-3-deaza-AMP
-
1.7% of the activity with adenosine
-
-
?
ATP + 2-fluoro-3-deazaadenosine
ADP + 2-fluoro-3-deazaadenosine 5'-phosphate
-
specific activity 63 nM/mg/min
-
-
?
ATP + 2-fluoro-9-[beta-D-arabinofuranosyl]-adenine
ADP + 2-fluoro-9-[beta-D-arabinofuranosyl]-AMP
0.9% of the activity with adenosine
-
-
?
ATP + 2-fluoro-adenosine
?
-
75% of the activity with adenosine
-
-
?
ATP + 2-fluoro-adenosine
ADP + 2-fluoro-AMP
52% of the activity with adenosine
-
-
?
ATP + 2-fluoroadenosine
ADP + 2-fluoroadenosine 5'-phosphate
ATP + 2-isopropylamino-N6-isopropyladenosine
ADP + 2-isopropylamino-N6-isopropyladenosine 5'-phosphate
-
81% of the activity with adenosine
-
-
?
ATP + 2-isopropylaminoadenosine
ADP + 2-isopropylaminoadenosine 5'-phosphate
-
4% of the activity with adenosine
-
-
?
ATP + 2-methyl-adenosine
?
-
0.14% of the activity with adenosine
-
-
?
ATP + 2-methyl-adenosine
ADP + 2-methyl-AMP
2% of the activity with adenosine
-
-
?
ATP + 2-methyladenosine
ADP + 2-methyl-AMP
ATP + 3'-amino-3'-deoxyadenosine
ADP + 3'-amino-3'-deoxyadenosine 5'-phosphate
ATP + 3-deazaadenosine
ADP + 3-deaza-AMP
-
0.03% of the activity with adenosine
-
-
?
ATP + 3-deazaadenosine
ADP + 3-deazaadenosine 5'-phosphate
-
specific activity 1 nM/mg/min
-
-
?
ATP + 3-fluoro-3-deaza-adenosine
ADP + 3-fluoro-3-deaza-AMP
ATP + 3-fluoro-3-deazaadenosine
ADP + 3-fluoro-3-deazaadenosine 5'-phosphate
ATP + 3-[beta-D-ribofuranosyl]-adenine
?
-
11.2% of the activity with adenosine
-
-
?
ATP + 3-[beta-D-ribofuranosyl]-adenine
ADP + 3-[beta-D-ribofuranosyl]-AMP
0.7% of the activity with adenosine
-
-
?
ATP + 4'-thioadenosine
ADP + 4'-thioadenosine 5'-phosphate
-
-
-
-
?
ATP + 6-bromopurine riboside
ADP + 6-bromopurine riboside 5'-phosphate
-
-
-
-
?
ATP + 6-chloropurine riboside
ADP + 6-chloropurine riboside 5'-phosphate
ATP + 6-fluoromethylpurine riboside
ADP + 6-fluoromethylpurine riboside 5'-phosphate
-
-
-
-
?
ATP + 6-methyl-purine riboside
?
-
41% of the activity with adenosine
-
-
?
ATP + 6-methyl-purine riboside
ADP + 6-methylpurine-D-riboside 5'-phosphate
2.75% of the activity with adenosine
-
-
?
ATP + 6-methylmercaptopurine riboside
ADP + 6-methylmercaptopurine-D-riboside 5'-phosphate
ATP + 8-aza-9-deazaadenosine
ADP + 8-aza-9-deazaadenosine 5'-phosphate
ATP + 8-aza-adenosine
?
-
38% of the activity with adenosine
-
-
?
ATP + 8-aza-adenosine
ADP + 8-aza-AMP
4% of the activity with adenosine
-
-
?
ATP + 8-aza-carbocyclic-adenosine
?
-
26% of the activity with adenosine
-
-
?
ATP + 8-aza-carbocyclic-adenosine
ADP + 8-aza-carbocyclic-AMP
4% of the activity with adenosine
-
-
?
ATP + 8-azaadenosine
ADP + 8-azaadenosine 5'-phosphate
-
-
-
-
?
ATP + 9-[alpha-L-lyxofuranosyl]-2-fluoro-adenine
ADP + 9-[alpha-L-lyxofuranosyl]-2-fluoro-AMP
3.3% of the activity with adenosine
-
-
?
ATP + 9-[alpha-L-lyxofuranosyl]-adenine
?
-
15% of the activity with adenosine
-
-
?
ATP + 9-[alpha-L-lyxofuranosyl]-adenine
ADP + 9-[alpha-L-lyxofuranosyl]-AMP
3.8% of the activity with adenosine
-
-
?
ATP + 9-[beta-D-5-methyl-(allo)-ribofuranosyl]-2-fluoro-adenine
ADP + 9-[beta-D-5-methyl-(allo)-ribofuranosyl]-2-fluoro-AMP
0.1% of the activity with adenosine
-
-
?
ATP + 9-[beta-D-arabinofuranosyl]-adenine
?
-
0.25% of the activity with adenosine
-
-
?
ATP + 9-[beta-D-arabinofuranosyl]-adenine
ADP + 9-[beta-D-arabinofuranosyl]-adenine 5'-phosphate
0.6% of the activity with adenosine
-
-
?
ATP + 9-[beta-D-ribofuranosyl]-purine
ADP + 9-[beta-D-ribofuranosyl]-purine 5'-phosphate
ATP + adenosine
?
the obligate intracellular parasite Toxoplasma gondii is incapable of synthesizing purine nucleotides de novo and relies completely on purines salvaged from the host cells. Adenosine is the preferred precursor and is phosphorylated by adenosine kinase (AK), the most active enzyme in adenosine metabolism in Toxoplasma gondii
-
-
?
ATP + adenosine
ADP + AMP
ATP + adenosine-1-N-oxide
ADP + adenosine-1-N-oxide 5'-phosphate
ATP + adenosine-N1-oxide
ADP + adenosine-N1-oxide 5'-phosphate
-
-
-
-
?
ATP + ADP
ADP + ATP
-
-
traces of ATP formed
?
ATP + AMP
ADP + ADP
-
-
45% of ADP formed
?
ATP + arabinofuranosyladenine
ADP + arabinofuranosyladenine 5'-phosphate
-
-
-
-
?
ATP + aristeromycin
?
-
37% of the activity with adenosine
-
-
?
ATP + aristeromycin
ADP + aristeromycin 5'-phosphate
37.5% of the activity with adenosine
-
-
?
ATP + cordycepin
ADP + cordycepin 5'-phosphate
ATP + cytidine
?
-
-
-
-
?
ATP + deoxyadenosine
ADP + deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + ethenoadenosine
ADP + etheno-AMP
-
-
-
-
?
ATP + fludarabine
ADP + fludarabine 5'-phosphate
-
-
-
-
?
ATP + formycin A
ADP + formycin A 5'-phosphate
ATP + guanosine
?
-
-
-
-
?
ATP + inosine
ADP + inosine 5'-phosphate
ATP + N1-oxy-N6-methyladenosine
ADP + N1-oxy-N6-methyladenosine 5'-phosphate
-
-
-
-
?
ATP + N6-delta2-isopentenyl-adenosine
ADP + N6-delta2-isopentenyl-adenosine 5'-phosphate
-
-
-
-
?
ATP + N6-methyl-3'-deoxyadenosine
ADP + N6-methyl-3'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + N6-methyladenosine
ADP + N6-methyladenosine 5'-phosphate
ATP + ribavirin
ADP + ribavirin 5'-phosphate
ATP + toyocamycin
ADP + toyocamycin 5'-phosphate
-
-
-
-
?
ATP + tubercidin
ADP + tubercidin 5'-phosphate
ATP + uridine
?
-
-
-
-
?
ATP + viramidine
ADP + viramidine 5'-phosphate
-
very low activity
-
-
?
ATP + xylofuranosyladenine
ADP + xylofuranosyladenine 5'-phosphate
-
-
-
-
?
CTP + adenosine
CDP + AMP
dADP + adenosine
dAMP + AMP
28.5% conversion
-
-
?
dGTP + adenosine
dGDP + AMP
4.7fold higher activity compared to ATP
-
-
?
GDP + adenosine
GMP + AMP
21.1% conversion
-
-
?
GTP + adenosine
GDP + AMP
ITP + adenosine
IDP + AMP
TTP + adenosine
TDP + AMP
UDP + adenosine
UMP + AMP
5.9% conversion
-
-
?
UTP + adenosine
UDP + AMP
additional information
?
-
ATP + 2'-deoxy-2,2'-difluoro-adenosine
ADP + 2'-deoxy-2,2'-difluoro-AMP
0.5% of the activity with adenosine
-
-
?
ATP + 2'-deoxy-2,2'-difluoro-adenosine
ADP + 2'-deoxy-2,2'-difluoro-AMP
0.5% of the activity with adenosine
-
-
?
ATP + 2'-deoxy-adenosine
?
-
-
-
-
?
ATP + 2'-deoxy-adenosine
?
-
3% of the activity with adenosine
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
-
-
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
-
-
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
-
-
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
0.3% of the activity with adenosine
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
0.3% of the activity with adenosine
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
-
-
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
-
-
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
-
-
-
-
?
ATP + 2'-deoxy-adenosine
ADP + 2'-deoxy-AMP
-
-
-
-
?
ATP + 2,3-difluoro-3-deaza-7-iso-adenosine
ADP + 2,3-difluoro-3-deaza-7-iso-AMP
-
0.2% of the activity with adenosine
-
-
?
ATP + 2,3-difluoro-3-deaza-7-iso-adenosine
ADP + 2,3-difluoro-3-deaza-7-iso-AMP
-
0.03% of the activity with adenosine
-
-
?
ATP + 2,3-difluoro-3-deaza-7-isoadenosine
ADP + 2,3-difluoro-3-deaza-7-isoadenosine 5'-phosphate
-
specific activity: 5 nM/mg/min
-
-
?
ATP + 2,3-difluoro-3-deaza-7-isoadenosine
ADP + 2,3-difluoro-3-deaza-7-isoadenosine 5'-phosphate
-
specific activity1 1 nM/mg/min
-
-
?
ATP + 2,3-difluoro-3-deaza-adenosine
ADP + 2,3-difluoro-3-deaza-AMP
-
0.2% of the activity with adenosine
-
-
?
ATP + 2,3-difluoro-3-deaza-adenosine
ADP + 2,3-difluoro-3-deaza-AMP
-
2.2% of the activity with adenosine
-
-
?
ATP + 2,3-difluoro-3-deazaadenosine
ADP + 2,3-difluoro-3-deazaadenosine 5'-phosphate
-
specific activity: 1 nM/mg/min
-
-
?
ATP + 2,3-difluoro-3-deazaadenosine
ADP + 2,3-difluoro-3-deazaadenosine 5'-phosphate
-
specific activity 81 nM/mg/min
-
-
?
ATP + 2-amino-carbocyclic-adenosine
ADP + 2-amino-carbocyclic-AMP
0.4% of the activity with adenosine
-
-
?
ATP + 2-amino-carbocyclic-adenosine
ADP + 2-amino-carbocyclic-AMP
0.4% of the activity with adenosine
-
-
?
ATP + 2-azaadenosine
ADP + 2-azaadenosine 5'-phosphate
-
-
-
-
?
ATP + 2-azaadenosine
ADP + 2-azaadenosine 5'-phosphate
-
-
-
-
?
ATP + 2-chloro-adenosine
ADP + 2-chloro-AMP
11.5% of the activity with adenosine
-
-
?
ATP + 2-chloro-adenosine
ADP + 2-chloro-AMP
11.5% of the activity with adenosine
-
-
?
ATP + 2-chloroadenosine
ADP + 2-chloroadenosine 5'-phosphate
-
-
-
-
?
ATP + 2-chloroadenosine
ADP + 2-chloroadenosine 5'-phosphate
-
-
-
-
?
ATP + 2-fluoroadenosine
ADP + 2-fluoroadenosine 5'-phosphate
-
-
-
-
?
ATP + 2-fluoroadenosine
ADP + 2-fluoroadenosine 5'-phosphate
-
-
-
-
?
ATP + 2-fluoroadenosine
ADP + 2-fluoroadenosine 5'-phosphate
-
-
-
-
?
ATP + 2-methyladenosine
ADP + 2-methyl-AMP
activation of 2-mehyladenosine
-
-
?
ATP + 2-methyladenosine
ADP + 2-methyl-AMP
30fold lower activity compared to adenosine
-
-
?
ATP + 2-methyladenosine
ADP + 2-methyl-AMP
activation of 2-mehyladenosine
-
-
?
ATP + 3'-amino-3'-deoxyadenosine
ADP + 3'-amino-3'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 3'-amino-3'-deoxyadenosine
ADP + 3'-amino-3'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 3-fluoro-3-deaza-adenosine
ADP + 3-fluoro-3-deaza-AMP
-
0.04% of the activity with adenosine
-
-
?
ATP + 3-fluoro-3-deaza-adenosine
ADP + 3-fluoro-3-deaza-AMP
-
0.4% of the activity with adenosine
-
-
?
ATP + 3-fluoro-3-deazaadenosine
ADP + 3-fluoro-3-deazaadenosine 5'-phosphate
-
specific activity: 1 nM/mg/min
-
-
?
ATP + 3-fluoro-3-deazaadenosine
ADP + 3-fluoro-3-deazaadenosine 5'-phosphate
-
specific activity 16 nM/mg/min
-
-
?
ATP + 6-chloropurine riboside
ADP + 6-chloropurine riboside 5'-phosphate
-
-
-
-
?
ATP + 6-chloropurine riboside
ADP + 6-chloropurine riboside 5'-phosphate
-
-
-
-
?
ATP + 6-methylmercaptopurine riboside
ADP + 6-methylmercaptopurine-D-riboside 5'-phosphate
-
-
-
-
?
ATP + 6-methylmercaptopurine riboside
ADP + 6-methylmercaptopurine-D-riboside 5'-phosphate
-
-
-
-
?
ATP + 8-aza-9-deazaadenosine
ADP + 8-aza-9-deazaadenosine 5'-phosphate
-
-
-
-
?
ATP + 8-aza-9-deazaadenosine
ADP + 8-aza-9-deazaadenosine 5'-phosphate
-
-
-
-
?
ATP + 9-[beta-D-ribofuranosyl]-purine
ADP + 9-[beta-D-ribofuranosyl]-purine 5'-phosphate
-
-
-
-
?
ATP + 9-[beta-D-ribofuranosyl]-purine
ADP + 9-[beta-D-ribofuranosyl]-purine 5'-phosphate
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is highly specific for adenosine and shows best activity with ATP as cosubstrate
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
the enzyme catalyzes the salvage synthesis of 5'-AMP from ADP and ATP
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is involved in adenosine and adenine salvage and interconversion of cytokinin ribosides and nucleotides, housekeeping enzymes, essential for maintainance of S-adenosyl-methionine-dependent transmethylation activities, metabolic role, overview
-
-
?
ATP + adenosine
ADP + AMP
adenosine kinase modulates root gravitropism and cap morphogenesis
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is involved in adenosine and adenine salvage and interconversion of cytokinin ribosides and nucleotides, metabolic role, overview
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is specific for nucleosides, it repels the entrance of phosphorylated sugars
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
adenosine kinase (ADK) is the first enzyme in the adenosine remediation pathway that catalyzes adenosine phosphorylation into adenosine monophosphate, thus regulating adenosine homeostasis in cells
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
specificity
-
-
?
ATP + adenosine
ADP + AMP
-
ATP-analogues are also substrates
-
-
?
ATP + adenosine
ADP + AMP
-
broad specificity for purine trinucleotides
-
-
?
ATP + adenosine
ADP + AMP
-
key enzyme for the regulation of intracellular adenosine level
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
purine salvage enzyme
-
-
?
ATP + adenosine
ADP + AMP
-
no phosphorylation of inosine or guanosine
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
reaction in salvage pathway for adenosine from nucleosides
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
specificity
-
-
?
ATP + adenosine
ADP + AMP
-
best substrates
-
?
ATP + adenosine
ADP + AMP
-
MgATP2- is the true substrate
-
-
?
ATP + adenosine
ADP + AMP
-
pyrimidine nucleoside triphosphates are less efficient than purine derivatives, deoxyribonucleotides less efficient than ribonucleotides
-
-
?
ATP + adenosine
ADP + AMP
-
specific activity: 2700 nM/mg/min
-
-
?
ATP + adenosine
ADP + AMP
intracellular adenosine, which is controlled by the key molecular regulator adenosine kinase, influences endothelial inflammation and vascular inflammatory diseases
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
best substrates
-
?
ATP + adenosine
ADP + AMP
-
best substrates
-
?
ATP + adenosine
ADP + AMP
-
specificity
-
?
ATP + adenosine
ADP + AMP
-
best substrates
-
?
ATP + adenosine
ADP + AMP
-
MgATP2- is the true substrate
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is involved in adenosine and adenine salvage and interconversion of cytokinin ribosides and nucleotides, metabolic role, overview
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
MgATP2- is the true substrate
-
-
?
ATP + adenosine
ADP + AMP
-
strictly specific for adenosine
-
?
ATP + adenosine
ADP + AMP
the major route of myocardial adenosine metabolism. Receptor-independent role of adenosine for adenosine kinase-mediated adenosine metabolism in cardiomyocyte microtubule dynamics and protection against maladaptive hypertrophy
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
purine salvage enzyme
-
-
?
ATP + adenosine
ADP + AMP
-
specific activity: 3700 nM/mg/min
-
-
?
ATP + adenosine
ADP + AMP
essential enzyme of Mycobacterium tuberculosis and forms part of the purine salvage pathway within mycobacteria
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
purine salvage enzyme
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
essential enzyme of Mycobacterium tuberculosis and forms part of the purine salvage pathway within mycobacteria
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme catalyzes the salvage synthesis of 5'-AMP from ADP and ATP
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
key enzyme in regulation of intracellular adenosine level, responsible, especially isozyme ADK2S, for the conversion of cytokinin ribosides into their respective nucleotides, accumulation of enzyme and increased activity just prior to mitosis is associated with a very active cytokinin metabolism at that phase of the cell cycle in cell culture, overview
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is involved in adenosine and adenine salvage and interconversion of cytokinin ribosides and nucleotides, part of the defense response against viral infection, metabolic role, overview
-
-
?
ATP + adenosine
ADP + AMP
ATP:Mg2+ ratio of 4:1
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
specificity
-
-
?
ATP + adenosine
ADP + AMP
-
best substrates
-
-
?
ATP + adenosine
ADP + AMP
-
MgATP2- is the true substrate
-
-
?
ATP + adenosine
ADP + AMP
-
ATP-analogues are also substrates
-
-
?
ATP + adenosine
ADP + AMP
-
6-N- and 6-S-substituted purine ribonucleosides and 4-substituted pyrazolo-3,4-d-pyrimidine ribonucleosides are also substrates but with low efficiencies
-
-
?
ATP + adenosine
ADP + AMP
-
involved in phosphorylation of many pharmacological active purine nucleosides
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is involved in adenosine and adenine salvage and interconversion of cytokinin ribosides and nucleotides, the metabolic route also utilizes exogenously fed and incorporated isopentenyladenosine involving the enzyme, metabolic role, overview
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is involved in adenosine and adenine salvage and interconversion of cytokinin ribosides and nucleotides, metabolic role, overview
-
-
?
ATP + adenosine
ADP + AMP
-
best substrates
-
?
ATP + adenosine
ADP + AMP
-
variation in activity during autumn-winter periods
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
MgATP2- is the true substrate
-
-
?
ATP + adenosine
ADP + AMP
-
key enzyme for the regulation of intracellular adenosine level
-
?
ATP + adenosine
ADP + AMP
-
the reverse reaction can be detected only if coupled with the adenosine deaminase reaction. This series of reactions transforms adenosine into inosine + NH3
-
-
r
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
MgATP2- is the true substrate
-
-
?
ATP + adenosine
ADP + AMP
-
key enzyme for the regulation of intracellular adenosine level
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
best substrates
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is involved in adenosine and adenine salvage and interconversion of cytokinin ribosides and nucleotides, metabolic role, overview
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
the enzyme is involved in adenosine and adenine salvage and interconversion of cytokinin ribosides and nucleotides, metabolic role, overview
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
-
enzyme shows highest activity of all enzymes involved in the adenosine salvage metabolism
-
-
?
ATP + adenosine
ADP + AMP
96.2% conversion
-
-
?
ATP + adenosine
ADP + AMP
-
-
55% of AMP formed
?
ATP + adenosine
ADP + AMP
-
-
-
-
?
ATP + adenosine
ADP + AMP
ATP is the preferred phosphoryl donor
-
-
?
ATP + adenosine
ADP + AMP
-
-
-
?
ATP + adenosine-1-N-oxide
ADP + adenosine-1-N-oxide 5'-phosphate
-
-
-
?
ATP + adenosine-1-N-oxide
ADP + adenosine-1-N-oxide 5'-phosphate
-
-
-
?
ATP + cordycepin
ADP + cordycepin 5'-phosphate
-
-
-
-
?
ATP + cordycepin
ADP + cordycepin 5'-phosphate
-
-
-
-
?
ATP + cordycepin
ADP + cordycepin 5'-phosphate
-
-
-
-
?
ATP + cordycepin
ADP + cordycepin 5'-phosphate
-
-
-
-
?
ATP + cordycepin
ADP + cordycepin 5'-phosphate
-
-
-
-
?
ATP + formycin A
ADP + formycin A 5'-phosphate
-
-
-
-
?
ATP + formycin A
ADP + formycin A 5'-phosphate
-
-
-
-
?
ATP + inosine
ADP + inosine 5'-phosphate
-
-
-
-
?
ATP + inosine
ADP + inosine 5'-phosphate
-
-
-
-
?
ATP + N6-methyladenosine
ADP + N6-methyladenosine 5'-phosphate
-
-
-
?
ATP + N6-methyladenosine
ADP + N6-methyladenosine 5'-phosphate
-
-
-
?
ATP + ribavirin
ADP + ribavirin 5'-phosphate
-
very low activity
-
-
?
ATP + ribavirin
ADP + ribavirin 5'-phosphate
-
-
-
-
?
ATP + tubercidin
ADP + tubercidin 5'-phosphate
-
-
-
-
?
ATP + tubercidin
ADP + tubercidin 5'-phosphate
-
-
-
-
?
ATP + tubercidin
ADP + tubercidin 5'-phosphate
-
-
-
-
?
ATP + tubercidin
ADP + tubercidin 5'-phosphate
-
-
-
-
?
CTP + adenosine
CDP + AMP
-
-
-
-
?
CTP + adenosine
CDP + AMP
-
about 60% of activity with ATP
-
-
?
CTP + adenosine
CDP + AMP
-
CTP is a poor substrate
-
?
CTP + adenosine
CDP + AMP
-
CTP is a poor substrate
-
?
CTP + adenosine
CDP + AMP
-
no activity with CTP as substrate
-
-
?
CTP + adenosine
CDP + AMP
-
CTP is a poor substrate
-
?
CTP + adenosine
CDP + AMP
-
CTP is a poor substrate
-
?
CTP + adenosine
CDP + AMP
-
-
-
?
CTP + adenosine
CDP + AMP
-
less efficient than ATP
-
?
CTP + adenosine
CDP + AMP
-
-
-
-
?
GTP + adenosine
GDP + AMP
-
-
-
-
?
GTP + adenosine
GDP + AMP
-
best substrate
-
?
GTP + adenosine
GDP + AMP
-
equally effective as ITP
-
?
GTP + adenosine
GDP + AMP
-
about 50% of activity with ATP
-
-
?
GTP + adenosine
GDP + AMP
-
-
-
?
GTP + adenosine
GDP + AMP
-
best substrate
-
?
GTP + adenosine
GDP + AMP
-
best substrate
-
?
GTP + adenosine
GDP + AMP
-
more effective than ATP
-
?
GTP + adenosine
GDP + AMP
-
more effective than ATP
-
?
GTP + adenosine
GDP + AMP
-
-
-
?
GTP + adenosine
GDP + AMP
-
-
-
?
GTP + adenosine
GDP + AMP
-
-
-
?
GTP + adenosine
GDP + AMP
-
best substrate
-
?
GTP + adenosine
GDP + AMP
2.5fold higher activity compared to ATP
-
-
?
GTP + adenosine
GDP + AMP
2.5fold higher activity compared to ATP
-
-
?
GTP + adenosine
GDP + AMP
-
-
-
?
GTP + adenosine
GDP + AMP
-
less efficient than ATP
-
-
?
GTP + adenosine
GDP + AMP
-
better activity than with ATP
-
?
GTP + adenosine
GDP + AMP
-
more effective than ATP
-
?
GTP + adenosine
GDP + AMP
-
less efficient than ATP
-
?
GTP + adenosine
GDP + AMP
-
-
-
-
?
GTP + adenosine
GDP + AMP
-
equally effective as ATP
-
?
ITP + adenosine
IDP + AMP
-
best substrate
-
?
ITP + adenosine
IDP + AMP
-
about half as effective as GTP
-
?
ITP + adenosine
IDP + AMP
-
-
-
?
ITP + adenosine
IDP + AMP
-
about half as effective as ATP
-
?
ITP + adenosine
IDP + AMP
-
about half as effective as GTP
-
?
ITP + adenosine
IDP + AMP
-
about half as effective as ATP
-
?
ITP + adenosine
IDP + AMP
-
better activity than with ATP
-
?
ITP + adenosine
IDP + AMP
-
less than with ATP
-
-
?
ITP + adenosine
IDP + AMP
-
less than with ATP
-
-
?
ITP + adenosine
IDP + AMP
-
less than with ATP
-
?
TTP + adenosine
TDP + AMP
-
-
-
-
?
TTP + adenosine
TDP + AMP
-
about 10% of activity with ATP
-
-
?
UTP + adenosine
UDP + AMP
-
-
-
-
?
UTP + adenosine
UDP + AMP
-
about 40% of activity with ATP
-
-
?
UTP + adenosine
UDP + AMP
-
UTP is a poor substrate
-
?
UTP + adenosine
UDP + AMP
-
UTP is a poor substrate
-
?
UTP + adenosine
UDP + AMP
-
no activity with UTP as substrate
-
-
?
UTP + adenosine
UDP + AMP
-
UTP is a poor substrate
-
?
UTP + adenosine
UDP + AMP
-
-
-
?
UTP + adenosine
UDP + AMP
-
-
-
-
?
UTP + adenosine
UDP + AMP
-
less efficient than ATP
-
?
UTP + adenosine
UDP + AMP
-
no activity with UTP as substrate
-
-
?
UTP + adenosine
UDP + AMP
-
no activity with UTP as substrate
-
-
?
UTP + adenosine
UDP + AMP
-
-
-
-
?
additional information
?
-
-
the organism prefers the minor route of adenosine salvage/recycling via adenosine deaminase, EC 3.5.4.4, and adenosine nucleosidase, EC 3.2.2.9, compared to the major route via adenosine kinase, overview
-
-
?
additional information
?
-
-
development of methods for analyzing the enzymatic reaction of adenosine kinase. These methods allow to measure substrates and potential inhibitors for adenosine kinase within a few min with high accuracy and reproducibility by means of capillary electrophoresis
-
-
?
additional information
?
-
-
hypoxia inducible factor 1-alpha-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak
-
-
?
additional information
?
-
-
cyclophilin (LdCyP) dislocated into the cytoplasm of the stressed cells most likely is responsible for reactivation of the AdK activity. R147 of cyclophilin is the most crucial residue in the LdCyP-AdK interaction
-
-
?
additional information
?
-
-
under the condition of cellular stress, the ER-located cyclophilins LdCyP is released into the cytoplasm with concomitant increase both in the specific activity of the cytosol-resident AdK and the uptake of radiolabeled Ado into the cells
-
-
?
additional information
?
-
-
low levels of ADK are essential to maintain adenosine-mediated neuroprotection
-
-
?
additional information
?
-
dATP, UTP, dTTP, CTP, and dCTP are poor phosphate donors
-
-
?
additional information
?
-
-
dATP, UTP, dTTP, CTP, and dCTP are poor phosphate donors
-
-
?
additional information
?
-
dATP, UTP, dTTP, CTP, and dCTP are poor phosphate donors
-
-
?
additional information
?
-
-
adenosine kinase suppresses sporulation and actinorhodin biosynthesis while inducing hyperproduction of undecylprodigiosin in Streptomyces lividans
-
-
?
additional information
?
-
hybrid random bi-uni ping-pong uni-bi mechanism, with substrate-enzyme-cosubstrate complex formation, binding pattern indicates that binding of the substrate interferes with the binding of the cosubstrate and vice versa. For every ATP consumed, the enzyme generates three AMPs
-
-
?
additional information
?
-
-
hybrid random bi-uni ping-pong uni-bi mechanism, with substrate-enzyme-cosubstrate complex formation, binding pattern indicates that binding of the substrate interferes with the binding of the cosubstrate and vice versa. For every ATP consumed, the enzyme generates three AMPs
-
-
?
additional information
?
-
-
the enzyme plays a role in susceptibility to adenosine antimetabolites
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+)-6-ethyl-6-[4-[(2,6-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2,3,5,6-tetrafluorophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2,3-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2,4-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2,4-difluorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2,5-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2,5-dimethoxyphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2,6-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-chloro-4-fluorophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-chloro-4-iodophenyloxy)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-chloro-4-iodophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-chlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
6.5% inhibition at 0.015 mM
(+/-)-6-ethyl-6-[4-[(2-chlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]thiazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-fluorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-imidazolylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-methyl-6-chlorophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-pyrazylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-pyridylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(2-pyrimidylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(3,4-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(3-chloro-4-fluorophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(3-chlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(3-fluorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(3-methoxyphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(3-methylphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(3-trifluoromethoxyphenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo [1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(3-trifluoromethylphenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(4-bromophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(4-ethynylphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
16% inhibition at 0.015 mM
(+/-)-6-ethyl-6-[4-[(4-fluorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
13% inhibition at 0.015 mM
(+/-)-6-ethyl-6-[4-[(4-iodophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(4-iodophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]thiazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(4-methoxyphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(4-nitrophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(4-trifluoromethoxyphenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[(phenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
15% inhibition at 0.015 mM
(+/-)-6-ethyl-6-[4-[3-(2-diethylaminoethyl)phenoxymethyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[3-(2-hydroxye)thylphenoxymethyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[3-(2-pyrrolidin-1-ylethyl)phenoxymethyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[[4-[2-(trimethylsilyl)ethynyl]phenylthio]-methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-ethyl-6-[4-[[4-[2-(trimethylsilyl)ethynyl]phenylthio]-methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]thiazepin-7-one
-
-
(+/-)-6-[4-[(2-chlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-[4-[(3-trifluoromethylphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(+/-)-6-[4-[(phenylthio)methyl]phenyl]-6,7-dihydrobenzo-[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(-)-6-ethyl-6-[4-[(2,6-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
-
-
(1R,2R,3S,4R,5S)-4-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 82.5% inhibition
(1R,2R,3S,4R,5S)-4-(4-anilino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 85.4% inhibition
(1R,2S,3R,4R,5S)-1-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(aminomethyl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 50.9% inhibition
(1R,2S,3R,4R,5S)-1-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(azidomethyl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 80.5% inhibition
(1R,2S,3R,4R,5S)-1-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 58.2% inhibition
(1R,2S,3R,4R,5S)-1-(4-anilino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 85.1% inhibition
(1R,2S,3R,4R,5S)-1-(4-anilino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 88.3% inhibition
(1R,2S,3R,4R,5S)-1-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 76.5% inhibition
(1R,2S,3R,4S,5S)-1-(4-anilino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-methylbicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 88.1% inhibition
(1R,2S,3R,4S,5S)-1-[4-(4-fluoroanilino)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-4-methylbicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 86.9% inhibition
(1R,2S,3R,4S,5S)-1-[4-anilino-5-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-4-methylbicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 78.4% inhibition
(1R,2S,3R,4S,5S)-4-amino-1-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[3.1.0]hexane-2,3-diol
0.05 mM, 60.4% inhibition
(1R,2S,3R,5R)-3-(6-(4-([1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol
-
(1S,2R,3S,5R)-3-amino-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
0.05 mM, 88.4% inhibition
(2R,3R,4R)-2-[5-phenyl-4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]tetrahydrofuran-3,4-diol
-
(2R,3R,4S,5R)-2-(6-(4-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
-
(2R,3R,4S,5R)-2-(6-(4-([1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
-
(2R,3R,4S,5R)-2-(6-([1,1'-biphenyl]-4-ylethynyl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol
-
compound displays very significant antimycobacterial activity, IC50 value 0.3 microM, but shows the highest cytotoxicity of the compounds tested. Compound only weakly inhibits in vitro adenosine kinase
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(3'-(morpholinomethyl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4'-(2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4-(6-methoxypyridin-3-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(phenylethynyl)phenyl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[4-(1H-imidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]tetrahydrofuran-3,4-diol
-
compound exhibits moderate antimycobacterial activity, IC50 value 15.6 microM, accompanied by preferentialinhibition of adenosine kinase and low cytotoxicity
(2S,3S,4R,5R)-2-amino-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol
-
-
1-(4-fluorobenzyloxy)-adenosine
-
0.1 mM, 10-90% inhibition
1-deaza-2-amino-6-chloropurine riboside
-
0.1 mM, 10-90% inhibition
10-(dimethylamino)-6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7(6H)-one
-
-
2',3',5'-tri-O-acetyl-adenosine
10-90% inhibition at 0.1 mM
2',3'-isopropylidene adenosine
-
weak inhibition
2'-deoxy-2,2'-difluoro-adenosine
10-90% inhibition at 0.1 mM
2'-deoxy-adenosine
10-90% inhibition at 0.1 mM
2'-deoxycoformycin
-
0.1 mM, 10-90% inhibition
2'-O-methyl-adenosine
10-90% inhibition at 0.1 mM
2,3-difluoro-3-deaza-7-iso-adenosine
2,3-difluoro-3-deaza-7-isoadenosine
-
0.1 mM, 18% inhibition of phosphorylation of adenosine
2,3-difluoro-3-deaza-adenosine
-
0.1 mM, 12% inhibition
2,3-difluoro-3-deazaadenosine
-
0.1 mM, 12% inhibition of phosphorylation of adenosine
2,4,6-trimethyl-6-benzylthioinosine
-
-
2,4-dichloro-6-benzylthioinosine
-
-
2,N6-dimethyladenosine
-
0.1 mM, 10-90% inhibition
2,O6-dimethylinosine
-
0.01 mM, 10-90% inhibition
2-(1-ethyn-1-yl)-adenosine
-
0.1 mM, 10-90% inhibition
2-amino-6-oxypurine riboside
-
0.1 mM, 10-90% inhibition
2-Aminoadenosine
-
0.1 mM, 10-90% inhibition
2-azaadenosine
-
0.01 mM, 10-90% inhibition
2-azidoadenosine
-
0.01 mM, 10-90% inhibition
2-bromoadenosine
-
0.01 mM, 10-90% inhibition
2-carboxyethyl phosphonic acid
-
-
2-carboxyethylphosphonic acid
-
-
2-chloro-2'-deoxy-2'-fluoro-9-[beta-D-arabinofuranosyl]-adenine
10-90% inhibition at 0.1 mM
2-chloro-2'-deoxy-2'-fluoro-adenosine
10-90% inhibition at 0.01 mM
2-chloro-2'-deoxy-adenosine
10-90% inhibition at 0.1 mM
2-chloro-4'-thio-adenosine
10-90% inhibition at 0.1 mM
2-chloro-6-benzylthioinosine
-
-
2-chloro-6-fluoro-6-benzylthioinosine
-
-
2-chloro-6-methoxypurine riboside
-
0.01 mM, 10-90% inhibition
2-chloro-adenosine
10-90% inhibition at 0.01 mM
2-chloropurine riboside
-
0.1 mM, 10-90% inhibition
2-ethyladenosine
-
0.1 mM, 10-90% inhibition
2-fluoro-3-deaza-adenosine
2-fluoro-3-deaza-N6-methyl-adenosine
2-fluoro-3-deazaadenosine
2-fluoro-4-(benzofuran-2-yl)-7-(beta-d-ribofuranosyl)-7H-pyrrolo-[2,3-d]pyrimidine
-
potent and selective inhibition, moderate effect against whole cells. MIC value 62.5 microM
2-fluoro-6-benzylthioinosine
-
-
2-fluoro-8-azaadenosine
-
0.01 mM, 10-90% inhibition
2-fluoro-9-[beta-D-arabinofuranosyl]-adenine
10-90% inhibition at 0.1 mM
2-hydroxyadenosine
-
0.1 mM, 10-90% inhibition
2-methyl-6-benzylthioinosine
-
-
2-methyl-6-oxypurine riboside
-
0.001 mM, 10-90% inhibition
2-methyl-adenosine
10-90% inhibition at 0.1 mM
2-methyl-N6-benzoyladenosine
-
0.1 mM, 10-90% inhibition
2-methyl-N6-octyladenosine
-
0.01 mM, 10-90% inhibition
2-methyl-S6-phenyl-6-mercaptopurine riboside
-
0.1 mM, 10-90% inhibition
2-methyladenosine
-
0.1 mM, 10-90% inhibition
2-Phenylethylureidopurine ribonucleoside
-
competitive inhibition
2-tert-butyl-4H-benzo[1,2,4]thiadiazine-3-thione
-
36% inhibition at 0.002 mM, 68% inhibition at 0.004 mM, 83% inhibition at 0.01 mM
2-[2-(3,4-dihydroxy-phenyl)-5-phenyl-1H-imidazol-4-yl]-fluoren-9-one
-
87% inhibition at 0.002 mM, 89% inhibition at 0.004 mM, 96% inhibition at 0.01 mM
2-[3-(1H-benzoimidazol-2-yl)-6-methoxy-chromen-2-ylideneamino]-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amide
-
20% inhibition at 0.002 mM, 56% inhibition at 0.004 mM, 81% inhibition at 0.01 mM; 20% inhibition at 0.020 mM, 56% inhibition at 0.040 mM, 81% inhibition at 0.1 mM
3'-deoxy-3'-azido-adenosine
-
10-90% inhibition at 0.1 mM
3,4-dichloro-6-benzylthioinosine
-
-
3-chloro-3-deaza-adenosine
3-chloro-3-deazaadenosine
3-deaza-adenosine
-
0.1 mM, 6% inhibition
3-fluoro-3-deaza-adenosine
-
0.1 mM, 12% inhibition
3-fluoro-3-deazaadenosine
-
0.1 mM, 12% inhibition of phosphorylation of adenosine
3-methyl-6-benzylthioinosine
-
-
3-nitro-6-benzylthioinosine
-
-
3-trifluoromethyl-6-benzylthioinosine
-
-
3-[3-(4-hydroxy-phenyl)-4-oxo-2-thioxo-thiazolidin-5-ylidene]-1-methyl-1,3,3a,7a-tetrahydro-indol-2-one
-
68% at 0.020 mM, 88% inhibition at 0.04 mM, 98% inhibition at 0.1 mM; 68% inhibition at 0.002 mM, 88% inhibition at 0.004 mM, 98% inhibition at 0.01 mM
3-[5,6-bis-(4-methoxy-phenyl)-furo[2,3-d]pyrimidin-4-ylamino]-propan-1-ol
-
86% inhibition at 0.002 mM, 87% inhibition at 0.004 mM, 89% inhibition at 0.01 mM
3-[beta-D-ribofuranosyl]-adenine
10-90% inhibition at 0.01 mM
4-(1H-pyrazol-4-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
4-(furan-2-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
4-(furan-3-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
4-acetoxy-6-benzylthioinosine
-
-
4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine
-
-
4-Amino-5-imidazolecarboxamide riboside
-
-
4-amino-5-iodo-7-(4'-C-spirocyclopropyl-beta-D-erythropentofuranosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 600 nM
4-amino-5-iodo-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]-pyrimidine
-
IC50: 6 nM
4-amino-5-iodo-7beta-D-ribofuranosyl-7H-pyrrole(2,3-d)-pyrimidine
-
100% inhibition
4-bromo-6-benzylthioinosine
-
-
4-chloro-6-benzylthioinosine
-
-
4-cyano-6-benzylthioinosine
-
-
4-fluoro-6-benzylthioinosine
-
-
4-methoxy-6-benzylthioinosine
-
-
4-methyl-6-benzylthioinosine
-
-
4-N-(2-methoxyphenyl)amino-5-(4-ethoxyphenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 5.3 nM
4-N-(3,4-ethylenedioxyphenyl)amino-5-(2-methylphenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 1 nM
4-N-(3,4-ethylenedioxyphenyl)amino-5-phenyl-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 4 nM
4-N-(3-ethoxyphenyl)amino-5-phenyl-7-(beta-D-erythrofuranosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 2 nM
4-N-(4-bromophenyl)amino-5-phenyl-7-(beta-D-erythrofuranosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 5 nM
4-N-(4-cyanophenyl)amino-5-(4-chlorophenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 7 nM
4-N-(4-cyanophenyl)amino-5-(4-ethoxyphenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 2 nM
4-N-(4-ethoxyphenyl)amino-5-phenyl-7-(beta-D-erythrofuranosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 3 nM
4-N-(4-fluorophenyl)amino-5-(3-aminophenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 10 nM
4-N-(4-fluorophenyl)amino-5-phenyl-7-(4'-C-spirocyclopropyl-beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 0.3 nM
4-N-(4-fluorophenyl)amino-5-phenyl-7-(beta-D-erythrofuranosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 6 nM
4-N-phenylamino-5-phenyl-7-(5'-deoxy-4'-C-methyl-beta-D-ribo-furanosyl)pyrrolo[2,3-d]pyrimidine
-
IC50: 4000 nM
4-N-phenylamino-5-phenyl-7-(beta-D-erythro-furanosyl)-pyrrolo[2,3-d]pyrimidine
-
IC50: 4 nM
4-nitro-6-benzylthioguanosine
-
0.2 mM, partial inhibition
4-nitro-6-benzylthioinosine
4-tert-butyl-6-benzylthioinosine
-
-
4-trifluoromethoxy-6-benzylthioinosine
-
-
5'-amino-5'-deoxy-adenosine
5'-amino-5'-deoxyadenosine
-
adenosine phosphorylation is inhibited by 100fold excess of the inhibitor
5'-carboxamido-adenosine
10-90% inhibition at 0.1 mM
5'-Deoxy-5'-aminoadenosine
-
strong, kinetic studies
5'-deoxy-5-iodotubercidin
-
following systemic administration, adenosine kinase inhibitors can alleviate acute thermal nociception as measured by the hot-plate test in mice
5'-deoxy-adenosine
10-90% inhibition at 0.01 mM
5-benzyl-6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]pyrimidin-4-amine
-
5-fluoro-4-(furan-2-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
5-fluoro-4-(furan-3-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
5-fluoro-7-(beta-D-ribofuranosyl)-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
5-fluoro-7-(beta-D-ribofuranosyl)-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine
5-iodo-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
0.05 mM, 88.3% inhibition
5-[4-(dimethylamino)phenyl]-6-{[6-(morpholin-4-yl)pyridin-3-yl]ethynyl}pyrimidin-4-amine
-
6,8-bis(anilin-N-yl)-9-(beta-D-ribofuranosyl)purine
-
IC50: 90 nM
6,8-bis(indolin-N-yl)-9-(beta-D-ribofuranosyl)purine
-
IC50: 2000 nM
6-(4-[[(2-chlorophenyl)sulfanyl]methyl]phenyl)-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
binds to a putative allosteric site
6-benzylmercaptopurine riboside
6-bromopurine riboside
-
0.01 mM, 10-90% inhibition
6-Chloropurine riboside
-
0.01 mM, 10-90% inhibition
6-cyclopentyloxypurine riboside
6-dimethylaminopurine riboside
-
-
6-ethyl-6-(3-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7(6H)-one
-
-
6-ethyl-6-(4-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7(6H)-one
-
-
6-ethyl-6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7(6H)-one
-
-
6-ethyl-6-[4-[(phenylsulfanyl)methyl]phenyl]-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
binds to a putative allosteric site
6-fluoro-8-aminopurine riboside
-
0.1 mM, 10-90% inhibition
6-fluoromethylpurine riboside
-
0.01 mM, 10-90% inhibition
6-gamma,gamma-dimethylallylaminopurine riboside
-
90% inhibition
6-indolin-N-yl-8-chloro-9-(beta-D-ribofuranosyl)purine
-
IC50: 480 nM
6-indolin-N-yl-8-iodo-9-(beta-D-ribofuranosyl)purine
-
IC50: 1000 nM
6-indolin-N-yl-8-methylthio-9-(beta-D-ribofuranosyl)-purine
-
IC50: 150 nM
6-indolin-N-yl-8-vinyl-9-(beta-D-ribofuranosyl)purine
-
IC50: 60 nM
6-iodopurine riboside
-
0.1 mM, 10-90% inhibition
6-mercaptopurine riboside
6-methyl-purine riboside
10-90% inhibition at 0.01 mM
6-methylaminopurine riboside
-
-
6-Methylmercaptopurine riboside
6-methylmercaptopurine riboside phosphate
6-methylpurine riboside
-
0.01 mM, 10-90% inhibition
6-nitrobenzylmercaptopurine riboside
6-phenyl-6,7-dihydropyrrolo[2,1-d][1,5]benzothiazepin-7-yl acetate
-
-
6-phenyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepin-7-yl acetate
-
-
6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7(6H)-one
-
-
6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7(6H)-one
-
-
6-Ureidopurine ribonucleosides
-
-
6-[4-[(2-chloro-4-iodophenoxy)methyl]phenyl]-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
binds to a putative allosteric site
6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]-5-(2-phenylethyl)pyrimidin-4-amine
-
6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]-5-(3-phenylpropyl)pyrimidin-4-amine
-
6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]-5-(4-phenylbutyl)pyrimidin-4-amine
-
6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]pyrimidin-4-amine hydrate (1:1)
-
7-(2-naphthyl)-7-deazaadenine
7-(3-dibenzo[b,d]furanyl)-7-deazaadenine
submicromolar Mycobacterium tuberculosis-specific inhibitor, and active against Mycobacterium tuberculosis strains with a MIC of 4 microM
7-(beta-D-ribofuranosyl)-4-(1,3-thiazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
7-(beta-D-ribofuranosyl)-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
7-(beta-D-ribofuranosyl)-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine
7-beta-D-ribofuranosyl-pyrrolo-(2,3-d)-pyrimidine
-
competitive with respect to 6-methylmercaptopurine riboside and noncompetitive with respect to ATP
7-deaza-7-carboxamidoadenosine
-
0.01 mM, 10-90% inhibition
7-deaza-carbocyclic-adenosine
10-90% inhibition at 0.1 mM
7-deazaadenosine
-
0.01 mM, 10-90% inhibition
7-[4-([1,1'-biphenyl]-4-yl)piperazin-1-yl]-3-beta-D-ribofuranosyl-3H-imidazo[4,5-b]pyridine
-
7-[alpha-D-arabinofuranosyl]-adenine
10-90% inhibition at 0.1 mM
7-[alpha-D-ribofuranosyl]-adenine
10-90% inhibition at 0.1 mM
8-acetylenyl-6-indolin-N-yl-9-(beta-D-ribofuranosyl)-purine
-
IC50: 1000 nM
8-aminopurine riboside
-
0.1 mM, 10-90% inhibition
8-anilin-N-yl-6-indolin-N-yl-9-(5-deoxy-beta-D-ribofuranosyl)purine
-
IC50: 200 nM
8-anilin-N-yl-6-indolin-N-yl-9-(beta-D-ribofuranosyl)-purine
-
IC50: 19 nM
8-aza-2'-deoxy-adenosine
10-90% inhibition at 0.1 mM
8-aza-8-[beta-D-ribofuranosyl]-adenine
10-90% inhibition at 0.1 mM
8-aza-adenosine
10-90% inhibition at 0.01 mM, competitive inhibitor
8-aza-carbocyclic-adenosine
8-azaguanosine
-
weak inhibition
8-azidoadenosine
-
0.1 mM, 10-90% inhibition
8-azidopurine riboside
-
0.1 mM, 10-90% inhibition
8-Bromoadenosine
-
0.1 mM, 10-90% inhibition
8-bromopurine riboside
-
0.1 mM, 10-90% inhibition
8-chloroadenosine
-
0.1 mM, 10-90% inhibition
8-chloropurine riboside
-
0.1 mM, 10-90% inhibition
8-dimethylaminopurine riboside
-
0.1 mM, 10-90% inhibition
8-ethyl-6-indolin-N-yl-9-(beta-D-ribofuranosyl)purine
-
IC50: 230 nM
8-furan-2-yl-6-indolin-N-yl-9-(beta-D-ribofuranosyl)-purine
-
IC50: 2900 mM
8-hydroxypurine riboside
-
0.1 mM, 10-90% inhibition
8-mercaptopurine riboside
-
0.1 mM, 10-90% inhibition
8-methoxypurine riboside
-
0.1 mM, 10-90% inhibition
9-(2-deoxy-beta-D-erythropentopyranosyl)-adenine
10-90% inhibition at 0.1 mM
9-deazaadenosine
-
0.01 mM, 10-90% inhibition
9-[alpha-D-ribofuranosyl]-adenine
10-90% inhibition at 0.1 mM
9-[alpha-L-lyxofuranosyl]-2-fluoro-adenine
10-90% inhibition at 0.1 mM
9-[alpha-L-lyxofuranosyl]-adenine
10-90% inhibition at 0.1 mM
9-[beta-D-5-methyl-(allo)-ribofuranosyl]-2-fluoro-adenine
10-90% inhibition at 0.01 mM
9-[beta-D-5-methyl-(allo)-ribofuranosyl]-6-methyl-purine
10-90% inhibition at 0.01 mM
9-[beta-D-5-methyl-(talo)-ribofuranosyl]-2-fluoro-adenine
10-90% inhibition at 0.1 mM
9-[beta-D-5-methyl-(talo)-ribofuranosyl]-6-methyl-purine
10-90% inhibition at 0.1 mM
9-[beta-D-ribofuranosyl]purine
-
0.1 mM, 10-90% inhibition
adenosine-5'-pentaphospho-5'-adenosine
adenosine-5'-tetraphospho-5'-adenosine
adenosine-N1-oxide
-
0.1 mM, 10-90% inhibition
aristeromycin
10-90% inhibition at 0.1 mM
Begomovirus AL2
-
Begomovirus protein expressed in infected tobacco plants inactivates the adenosine kinase
-
Bisadenylyl polyphosphates
carbocyclic 6-(2,3,4-trimethylbenzylthio)inosine
-
-
carbocyclic 6-(2,4-dichlorobenzylthio)inosine
-
-
carbocyclic 6-(2-chloro-6-fluorobenzylthio)inosine
-
-
carbocyclic 6-(2-chlorobenzylthio)inosine
-
-
carbocyclic 6-(2-fluorobenzylthio)inosine
-
-
carbocyclic 6-(2-methylbenzylthio)inosine
-
-
carbocyclic 6-(3,4-dichlorobenzylthio)inosine
-
-
carbocyclic 6-(3-methylbenzylthio)inosine
-
-
carbocyclic 6-(3-nitrobenzylthio)inosine
-
-
carbocyclic 6-(3-trifluoromethylbenzylthio)inosine
-
-
carbocyclic 6-(4-bromobenzylthio)inosine
-
-
carbocyclic 6-(4-chlorobenzylthio)inosine
-
-
carbocyclic 6-(4-cyanobenzylthio)inosine
-
weakest inhibitor
carbocyclic 6-(4-fluorobenzylthio)inosine
-
-
carbocyclic 6-(4-methoxybenzylthio)inosine
-
-
carbocyclic 6-(4-methoxycarbonylbenzylthio)inosine
-
-
carbocyclic 6-(4-methylbenzylthio)inosine
-
-
carbocyclic 6-(4-methylsulfonylbenzylthio)inosine
-
-
carbocyclic 6-(4-nitrobenzylthio)inosine
-
-
carbocyclic 6-(4-trifluoromethoxybenzylthio)inosine
-
-
carbocyclic 6-(p-methoxycarbonylbenzylthio)inosine
-
-
carbocyclic 6-benzylthioinosine
-
-
clodronate
-
inhibits adenosine kinase activity in a dose-dependent manner in the presence of 10 mM phosphate
Curtovirus L2
-
Curtovirus protein expressed in infected tobacco plants inactivates the adenosine kinase
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-benzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thiazolyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-dibenzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-pyrazolyl)-7 H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
cyclohexyl-(2-thiophen-2-ylimidazo[1,2-a]pyrazin-3-yl)-amine
-
40% inhibition at 0.002 mM, 61% inhibition at 0.004 mM, 78% inhibition at 0.01 mM; 40%inhibition at 0.02 mM, 61% inhibition at 0.040 mM, 78% inhibition at 0.1 mM
cyclopentyl-(2-thiophen-2-ylimidazo[1,2-a]pyrazin-3-yl)-amine
-
57% at 0.020 mM, 66% inhibition at 0.04 mM, 73% inhibition at 0.1 mM; 57% inhibition at 0.002 mM, 66% inhibition at 0.004 mM, 73% inhibition at 0.01 mM
cytidine
-
0.1 mM, 10-90% inhibition
deoxymethylthioadenosine
-
weak inhibition
diethylphosphonoacetic acid
-
-
dipyridamole
-
at low adenosine levels
DTNB
-
substrates protect
etidronate
-
inhibits adenosine kinase activity in a dose-dependent manner in the presence of 10 mM phosphate
Formycin A
-
at very high concentrations, kinetics
GDP
-
non competitive with respect to adenosine and competitive with respect to ATP
Hg2+
-
strong inhibition, reducing agent reverses
K+
-
inhibition by increasing concentrations
methylphosphonic acid
-
-
MgADP-
-
product inhibition, linear, noncompetitive with respect to MgATP2- and adenosine
Mn2+
-
strong inhibition above 1 mM
N-(5,6-diphenyl-furo[2,3-d]pyrimidin-4-yl)-propionamide
-
40% inhibition at 0.002 mM, 61% inhibition at 0.004 mM, 78% inhibition at 0.01 mM
N-(phosphonomethyl)-glycine
-
-
N-(phosphonomethyl)iminodiacetic acid
-
-
N-phosphomethyl glycine
-
-
N-phosphomethyl iminodiacetic acid
-
-
N1-oxy-N6-methyladenosine
-
0.1 mM, 10-90% inhibition
N6-aminoadenosine
-
0.1 mM, 10-90% inhibition
N6-delta2-isopentenyl-adenosine
-
competitive with respect to adenosine
Na+
-
inhibition by increasing concentrations
Nucleoside analogs
-
overview
P1,P3-di(adenosine-5')triphosphate
-
-
P1,P4-di(adenosine-5')tetraphosphate
-
-
P1,P5-di(adenosine-5')pentaphosphate
-
Phenylglyoxal
-
inhibition levels of wild-type and mutant enzymes, overview
Polyclonal antibodies to adenosine kinase from Leishmania donovani
-
not from other eukaryotic sources
-
S-adenosylhomocysteine
-
97% inhibition
Xanthosine
-
weak inhibition
[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl]methyl octadecyl hydrogen phosphate
-
octadecylphosphate prodrug designed as lipophilic derivatives with increased penetration through the mycobacterial cell wall, no antimycobacterial activity
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(3'-(morpholinomethyl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(3'-(morpholinomethyl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
-
2'-deoxyadenosine
-
substrate inhibition
2'-deoxyadenosine
-
no inhibition
2,3-difluoro-3-deaza-7-iso-adenosine
-
0.1 mM, 18% inhibition
2,3-difluoro-3-deaza-7-iso-adenosine
-
0.1 mM, 4% inhibition
2-azido-O6-methylinosine
-
0.1 mM, 10-90% inhibition
2-azido-O6-methylinosine
-
0.001 mM, 10-90% inhibition
2-chloroadenosine
-
adenosine phosphorylation is inhibited by 100fold excess of the inhibitor
2-chloroadenosine
-
0.01 mM, 10-90% inhibition
2-fluoro-3-deaza-adenosine
-
0.1 mM, 9% inhibition
2-fluoro-3-deaza-adenosine
-
0.1 mM, 16% inhibition
2-fluoro-3-deaza-N6-methyl-adenosine
-
0.1 mM, 13% inhibition; 0.1 mM, 13% inhibition of phosphorylation of adenosine
2-fluoro-3-deaza-N6-methyl-adenosine
-
0.1 mM, 37% inhibition; 0.1 mM, 37% inhibition of phosphorylation of adenosine
2-fluoro-3-deazaadenosine
-
0.1 mM, 9% inhibition of phosphorylation of adenosine
2-fluoro-3-deazaadenosine
-
0.1 mM, 10-90% inhibition
2-fluoro-3-deazaadenosine
-
0.1 mM, 16% inhibition of phosphorylation of adenosine
2-fluoro-adenosine
-
10-90% inhibition at 0.1 mM
2-fluoro-adenosine
10-90% inhibition at 0.001 mM, competitive inhibitor
2-fluoroadenosine
-
0.1 mM, 10-90% inhibition
2-fluoroadenosine
-
0.001 mM, 10-90% inhibition
3'-deoxyadenosine
-
-
3'-deoxyadenosine
-
no inhibition
3-chloro-3-deaza-adenosine
-
0.1 mM, 9% inhibition
3-chloro-3-deaza-adenosine
-
0.1 mM, 71% inhibition
3-chloro-3-deazaadenosine
-
0.1 mM, 9% inhibition of phosphorylation of adenosine
3-chloro-3-deazaadenosine
-
0.1 mM, 71% inhibition of phosphorylation of adenosine
3-deazaadenosine
-
0.1 mM, 6% inhibition of phosphorylation of adenosine
3-deazaadenosine
-
0.1 mM, 10-90% inhibition
4-(1H-pyrazol-4-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
4-(1H-pyrazol-4-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
4-(furan-2-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
4-(furan-2-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
4-(furan-3-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
4-(furan-3-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
4-nitro-6-benzylthioinosine
-
0.2 mM, partial inhibition
4-nitro-6-benzylthioinosine
-
-
5'-amino-5'-deoxy-adenosine
-
10-90% inhibition at 0.001 mM
5'-amino-5'-deoxy-adenosine
-
following systemic administration, adenosine kinase inhibitors can alleviate acute thermal nociception as measured by the hot-plate test in mice
5'-amino-5'-deoxy-adenosine
10-90% inhibition at 0.001 mM, competitive inhibitor
5'-deoxyadenosine
-
adenosine phosphorylation is inhibited by 100fold excess of the inhibitor
5'-deoxyadenosine
-
100% inhibition
5-fluoro-4-(furan-2-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
5-fluoro-4-(furan-2-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
5-fluoro-4-(furan-3-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
5-fluoro-4-(furan-3-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
5-fluoro-7-(beta-D-ribofuranosyl)-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
5-fluoro-7-(beta-D-ribofuranosyl)-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
5-fluoro-7-(beta-D-ribofuranosyl)-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
5-fluoro-7-(beta-D-ribofuranosyl)-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
5-iodotubercidin
-
-
5-iodotubercidin
-
following systemic administration, adenosine kinase inhibitors can alleviate acute thermal nociception as measured by the hot-plate test in mice
6-benzylmercaptopurine riboside
-
0.1 mM, 10-90% inhibition
6-benzylmercaptopurine riboside
-
0.001 mM, 10-90% inhibition
6-cyclopentyloxypurine riboside
-
0.1 mM, 10-90% inhibition
6-cyclopentyloxypurine riboside
-
0.001 mM, 10-90% inhibition
6-mercaptopurine riboside
-
0.1 mM, 10-90% inhibition
6-mercaptopurine riboside
-
no inhibition
6-mercaptopurine riboside
-
weak inhibition
6-methoxypurine riboside
-
0.1 mM, 10-90% inhibition
6-methoxypurine riboside
-
0.001 mM, 10-90% inhibition
6-Methylmercaptopurine riboside
-
strong inhibition, substrate inhibition
6-Methylmercaptopurine riboside
-
0.1 mM, 10-90% inhibition
6-Methylmercaptopurine riboside
-
strong inhibition, substrate inhibition
6-Methylmercaptopurine riboside
-
and analogs
6-Methylmercaptopurine riboside
-
0.001 mM, 10-90% inhibition
6-methylmercaptopurine riboside phosphate
-
product inhibition, competitive with respect to ATP and noncompetitive with respect to 6-methylmercaptopurine ribonucleoside
6-methylmercaptopurine riboside phosphate
-
-
6-nitrobenzylmercaptopurine riboside
-
0.1 mM, 10-90% inhibition
6-nitrobenzylmercaptopurine riboside
-
0.001 mM, 10-90% inhibition
7-(2-naphthyl)-7-deazaadenine
most active compound against Mycobacterium tuberculosis strain My331/88 and drug-resistant strain Praha 131 in vitro, MIC is 2 or 4 microM, respectively, cytotoxic to human cells
7-(2-naphthyl)-7-deazaadenine
most active compound against Mycobacterium tuberculosis strain My331/88 and drug-resistant strain Praha 131 in vitro, MIC is 2 or 4 microM, respectively, cytotoxic to human cells
7-(beta-D-ribofuranosyl)-4-(1,3-thiazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
7-(beta-D-ribofuranosyl)-4-(1,3-thiazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
7-(beta-D-ribofuranosyl)-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
7-(beta-D-ribofuranosyl)-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
7-(beta-D-ribofuranosyl)-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
7-(beta-D-ribofuranosyl)-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
7-cyano-7-deazaadenosine
-
0.001 mM, 10-90% inhibition
7-cyano-7-deazaadenosine
-
0.001 mM, 10-90% inhibition
7-iodo-7-deazaadenosine
-
0.0001 mM, 10-90% inhibition
7-iodo-7-deazaadenosine
-
0.001 mM, 10-90% inhibition
8-aza-9-deazaadenosine
-
0.1 mM, 10-90% inhibition
8-aza-9-deazaadenosine
-
0.01 mM, 10-90% inhibition
8-aza-carbocyclic-adenosine
-
10-90% inhibition at 0.1 mM
8-aza-carbocyclic-adenosine
10-90% inhibition at 0.1 mM
8-azaadenosine
-
0.01 mM, 10-90% inhibition
adenosine
-
above 0.002 mM, at pH 7.5
adenosine
-
strongly inhibited by 100fold excess adenosine
adenosine
-
pH and Mg2+ dependent, most severe at pH 7.4, less inhibition at pH 8.0 and no inhibition at pH 6.5
adenosine
-
above 0.0025 mM, at pH 7.4, with ATP and Mg2+ 0.2 mM
adenosine
-
substrate inhibition above 0.0005 mM
adenosine
-
no inhibition
adenosine
-
no inhibition; strong, with formycin A as substrate
adenosine
-
competitive with respect to 6-methylmercaptopurine riboside
adenosine
substrate inhibition above 0.005 mM, 25% inhibition at 0.025 mM
adenosine
-
above 0.0005 mM
adenosine
-
substrate inhibition
adenosine
substrate inhibition, presence of ATP relieves substrate inhibition by adenosine
adenosine-5'-pentaphospho-5'-adenosine
-
competitive with respect to MgATP2- and uncompetitive with respect to adenosine
adenosine-5'-pentaphospho-5'-adenosine
-
-
adenosine-5'-tetraphospho-5'-adenosine
-
competitive with respect to ATP and uncompetitive with respect to adenosine
adenosine-5'-tetraphospho-5'-adenosine
-
strong inhibition
ADP
-
product inhibition
ADP
-
noncompetitive with respect to adenosine and ATP
ADP
-
noncompetitive with respect to ATP and 6-methylmercaptopurine ribonucleoside at low concentrations of the substrates; product inhibition
ADP
-
non competitive with respect to adenosine and competitive with respect to ATP; product inhibition
ADP
noncompetitive with adenosine, ADP and ATP show additive effects
AMP
-
product inhibition
AMP
-
product inhibition, above 5 mM
AMP
-
competitive with respect to adenosine and noncompetitive with respect to ATP
AMP
-
inhibits both D16V and D16N mutant enzymes to similar extents to that observed with the wild-type enzyme, displays a much reduced ability in inhibiting R131A mutant enzyme
AMP
-
mixed-type inhibition towards adenosine and ATP; product inhibition
AMP
competitive with ATP, noncompetitive with adenosine
ATP
-
free form
ATP
-
free form, above 0.5 mM
ATP
noncompetitive with adenosine, ADP and ATP show additive effects
Bisadenylyl polyphosphates
-
kinetics
Bisadenylyl polyphosphates
-
-
Cu2+
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-benzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-benzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thiazolyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thiazolyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-dibenzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-dibenzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-pyrazolyl)-7 H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-pyrazolyl)-7 H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
-
-
deoxyadenosine
-
-
deoxyguanosine
-
no inhibition
EDTA
-
EDTA
-
100 mM, complete inhibition
EDTA
-
at high concentrations
geminivirus AL2
inactivation of the enzyme in vitro and in vivo via direct interaction, AL2 is a RNA geminivirus of the Begomovirus genera encoded protein serving as pathogenicity determinant causing enhanced susceptibility of target organisms, overview
-
geminivirus AL2
-
inactivation of the enzyme in vitro and in vivo via direct interaction, AL2 is a RNA geminivirus of the Begomovirus genera encoded protein serving as pathogenicity determinant causing enhanced susceptibility of target organisms, overview
-
geminivirus L2
inactivation of the enzyme in vitro and in vivo via direct interaction, L2 is a RNA geminivirus of the Curtovirus genera encoded protein serving as pathogenicity determinant causing enhanced susceptibility of target organisms, overview
-
geminivirus L2
-
inactivation of the enzyme in vitro and in vivo via direct interaction, L2 is a RNA geminivirus of the Curtovirus genera encoded protein serving as pathogenicity determinant causing enhanced susceptibility of target organisms, overview
-
guanosine
-
no inhibition
guanosine
-
weak inhibition
iodotubercidin
-
-
iodotubercidin
competitive
Mg2+
-
free ion, strong
Mg2+
-
strong inhibition above 1 mM
Mg2+
-
at high concentrations
Mg2+
dependent on, optimal at 10-50 mM MgCl2, inhibitory above 50 mM
Mg2+
-
strong inhibition above 1 mM
N1-benzyladenosine
-
0.1 mM, 10-90% inhibition
N1-benzyladenosine
-
0.001 mM, 10-90% inhibition
N1-ethyladenosine
-
0.1 mM, 10-90% inhibition
N1-ethyladenosine
-
0.1 mM, 10-90% inhibition
N1-methyladenosine
-
0.1 mM, 10-90% inhibition
N1-methyladenosine
-
0.001 mM, 10-90% inhibition
NEM
-
moderate inhibition
NEM
-
moderate inhibition; strong inhibition with formycin A as substrate, adenosine protects
NEM
-
2-mercaptoethanol protects
Nucleosides
-
weak inhibition
p-hydroxymercuribenzoate
-
DTT reverses; strong inhibition
p-hydroxymercuribenzoate
-
2-mercaptoethanol reverses
p-hydroxymercuribenzoate
-
DTT reverses
Phosphonoacetic acid
-
64% inhibition at 8 mM, antagonized by phosphate
tubercidin
-
adenosine phosphorylation is inhibited by 100fold excess of the inhibitor
tubercidin
-
strong inhibition, substrate inhibition
uridine
-
weak inhibition
uridine
-
0.1 mM, 10-90% inhibition
additional information
-
9-beta-D-arabinofuranosyladenine analogue of adenosine at concentrations in 150fold excess over adenosine does not affect the enzyme activity
-
additional information
-
enzyme activity decreases by 5.5fold in senescent cell cultures, apoptosis does not influence enzyme levels
-
additional information
-
no inhibition by NaVO3; product inhibition study
-
additional information
-
development of methods for analyzing the enzymatic reaction of adenosine kinase. These methods allow to measure substrates and potential inhibitors for adenosine kinase within a few min with high accuracy and reproducibility by means of capillary electrophoresis
-
additional information
-
at pH 5.5, with equimolar concentrations of ATP and Mg2+ from 0.2 to 1 mM there is no inhibition by adenosine over a range of 0 to 0.02 mM; product inhibition study
-
additional information
-
a CoMSIA study on the adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues
-
additional information
synthesis of 7-(het)aryl-7-deazaadenine ribonucleosides bearing small and bulky substituents in position 7. Compounds bearing smaller substituents inhibit both human and Mycobacterium tuberculosis ADK and are cytotoxic, whereas several bulky derivatives are specific inhibitors of the Mycobacterium tuberculosis enzyme and are not cytotoxic
-
additional information
-
synthesis of 7-(het)aryl-7-deazaadenine ribonucleosides bearing small and bulky substituents in position 7. Compounds bearing smaller substituents inhibit both human and Mycobacterium tuberculosis ADK and are cytotoxic, whereas several bulky derivatives are specific inhibitors of the Mycobacterium tuberculosis enzyme and are not cytotoxic
-
additional information
-
no inhibition by S-adenosylhomocysteine, 2'-deoxycytidine, thymidine and cytidine
-
additional information
-
-
-
additional information
-
no inhibition by polyamines
-
additional information
synthesis of 7-(het)aryl-7-deazaadenine ribonucleosides bearing small and bulky substituents in position 7. Compounds bearing smaller substituents inhibit both human and Mycobacterium tuberculosis ADK and are cytotoxic, whereas several bulky derivatives are specific inhibitors of the Mycobacterium tuberculosis enzyme and are not cytotoxic
-
additional information
-
synthesis of 7-(het)aryl-7-deazaadenine ribonucleosides bearing small and bulky substituents in position 7. Compounds bearing smaller substituents inhibit both human and Mycobacterium tuberculosis ADK and are cytotoxic, whereas several bulky derivatives are specific inhibitors of the Mycobacterium tuberculosis enzyme and are not cytotoxic
-
additional information
-
inosine, aminonucleoside of puromycin, 2'-deoxyadenosine N1-oxide, 3'-deoxyadenosine N1-oxide, 8-aza-2'-deoxyadenosine, 2-aminopurine-2'-deoxyriboside, thioguanosine, psicofuranine, N6-methyl-2'-deoxyadenosine, N1-methyladenosine do not inhibit the enzyme activity
-
additional information
-
no inhibition by PMSF, EGTA
-
additional information
-
not influenced by DTT
-
additional information
-
IC50 values and toxicities, i.e. rates of survival, of the 6-benzylthioinosine derivatives in wild-type strain RH and in the mutant strain TgAK-3 in human fibrobalsts, effects of 6-benzylthioinosine and derivatives 2-cyano-6-benzylthioinosine and 2,4-dichloro-6-benzylthioinosine on survival of mice infected with the wild-type strain RH, overview
-
additional information
-
all the 7-deaza-6-benzylthioinosine analogues showed a selective antitoxoplasmic effect against wild type parasites, but not mutants lacking adenosine kinase
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0000275
(1R,2S,3R,5R)-3-(6-(4-([1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol
pH 7.5, temperature not specified in the publication
0.000023
(2R,3R,4S,5R)-2-(6-(4-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.0000053
(2R,3R,4S,5R)-2-(6-(4-([1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.000048
(2R,3R,4S,5R)-2-(6-([1,1'-biphenyl]-4-ylethynyl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.0000255 - 0.00041
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(3'-(morpholinomethyl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
0.0000189
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4'-(2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.0000213
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.000326 - 0.0016
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
0.0000185
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4-(6-methoxypyridin-3-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.0000199
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(phenylethynyl)phenyl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.00012 - 0.0051
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
0.00000006 - 0.00000009
(2S,3S,4R,5R)-2-amino-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol
0.01575
2'-deoxyadenosine
-
wild-type enzyme
0.15
2,4,6-trimethyl-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0007
2,4-dichloro-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0014
2-chloro-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0377
2-chloro-6-fluoro-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0005
2-fluoro-adenosine
-
0.0015
2-methyl-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0004
2-Phenylethylureidopurine ribonucleoside
-
-
0.0033
3'-deoxyadenosine
-
wild-type enzyme
0.0025
3,4-dichloro-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0013
3-methyl-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.003
3-nitro-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0029
3-trifluoromethyl-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.096
4-acetoxy-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0000014 - 0.0000017
4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine
0.0075
4-bromo-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0021
4-chloro-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0009
4-cyano-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0012
4-fluoro-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0026
4-methoxy-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0033
4-methyl-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0011
4-nitro-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.113
4-tert-butyl-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.141
4-trifluoromethoxy-6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.0008
5'-amino-5'-deoxy-adenosine
-
0.0000306
5-iodotubercidin
-
-
0.0024
6-benzylthioinosine
-
pH 7.4, 37°C, recombinant enzyme
0.00015
6-cyclopentyloxypurine riboside
0.16
6-methylmercaptopurine riboside phosphate
-
pH 6.0, 37ºC
0.015
7-beta-D-ribofuranosyl-pyrrolo-(2,3-d)-pyrimidine
-
pH 6.0, 37ºC
0.00021
7-iodo-7-deazaadenosine
0.0000163
7-[4-([1,1'-biphenyl]-4-yl)piperazin-1-yl]-3-beta-D-ribofuranosyl-3H-imidazo[4,5-b]pyridine
pH 7.5, temperature not specified in the publication
0.0058
8-aza-9-deazaadenosine
0.000073 - 0.002
adenosine-5'-pentaphospho-5'-adenosine
0.00003 - 0.0004
adenosine-5'-tetraphospho-5'-adenosine
0.000001 - 0.00021
iodotubercidin
0.00019
N1-benzyladenosine
0.061
P1,P3-di(adenosine-5')triphosphate
-
at 27°C in 50 mM Tris buffer (pH 7.4) containing 5 mM MgCl2, 50 mM KCl, and 0.2 mM dithiothreitol
0.00086
P1,P4-di(adenosine-5')tetraphosphate
-
at 27°C in 50 mM Tris buffer (pH 7.4) containing 5 mM MgCl2, 50 mM KCl, and 0.2 mM dithiothreitol
1.95
Phosphonoacetic acid
-
recombinant enzyme, pH 7.2, 37°C
additional information
additional information
-
development of methods for analyzing the enzymatic reaction of adenosine kinase. These methods allow to measure substrates and potential inhibitors for adenosine kinase within a few min with high accuracy and reproducibility by means of capillary electrophoresis
-
0.0000255
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(3'-(morpholinomethyl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.00041
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(3'-(morpholinomethyl)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.000326
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.0016
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-(4-(6-(trifluoromethyl)pyridin-3-yl)phenyl)piperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.00012
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.0051
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
pH 7.5, temperature not specified in the publication
0.00000006
(2S,3S,4R,5R)-2-amino-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol
-
Ki-value determined by on-line capillary electrophoresis
0.00000009
(2S,3S,4R,5R)-2-amino-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol
-
Ki-value determined by off-line capillary electrophoresis
0.0005
2-fluoroadenosine
-
-
0.0005
2-fluoroadenosine
-
-
0.0000014
4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine
-
Ki-value determined by off-line capillary electrophoresis
0.0000017
4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine
-
Ki-value determined by on-line capillary electrophoresis
0.00015
6-cyclopentyloxypurine riboside
-
-
0.00015
6-cyclopentyloxypurine riboside
-
-
0.00021
7-iodo-7-deazaadenosine
-
-
0.00021
7-iodo-7-deazaadenosine
-
-
0.0058
8-aza-9-deazaadenosine
-
-
0.0058
8-aza-9-deazaadenosine
-
-
0.0059 - 0.045
adenosine
-
pH 7.4, 37ºC, at variable AMP and Mg2+ concentrations
0.014
adenosine
-
pH 7.6, 37°C
0.051 - 0.238
adenosine
-
pH 8.0, 37ºC, at variable AMP and Mg2+ concentrations
0.26
adenosine
-
pH 6.0, 37ºC
0.000073
adenosine-5'-pentaphospho-5'-adenosine
-
pH 7.4, 37ºC
0.0004
adenosine-5'-pentaphospho-5'-adenosine
-
pH 7.5, 37ºC, with respect to MgATP2-
0.002
adenosine-5'-pentaphospho-5'-adenosine
-
pH 7.5, 37ºC, with respect to adenosine
0.00003
adenosine-5'-tetraphospho-5'-adenosine
-
pH 7.4, 37ºC
0.00006
adenosine-5'-tetraphospho-5'-adenosine
-
pH 7.5, 37ºC, with respect to ATP
0.0004
adenosine-5'-tetraphospho-5'-adenosine
-
pH 7.5, 37ºC, with respect to adenosine
0.011
ADP
-
pH 7.2, 37ºC, with variable MgATP2- and constant adenosine concentrations
0.2
ADP
-
pH 7.5, 37ºC, with respect to adenosine and MgATP2-
0.015
AMP
-
pH 7.5, 37ºC, with respect to adenosine
0.14
AMP
-
pH 7.4, 37ºC, at variable adenosine and saturating MgATP2- concentration
0.15
AMP
-
pH 7.5, 37ºC, with respect to MgATP2-
0.16
AMP
-
pH 7.2, 37ºC, with constant MgATP2- and variable adenosine concentrations
0.5
AMP
-
pH 7.4, 37ºC, at variable ATP and saturating adenosine concentration
1.84
AMP
-
pH 8.0, 37ºC, at variable adenosine concentrations
0.000001
iodotubercidin
-
at 27°C in 50 mM Tris buffer (pH 7.4) containing 5 mM MgCl2, 50 mM KCl, and 0.2 mM dithiothreitol
0.00021
iodotubercidin
pH 8.0, 37°C
0.03 - 0.534
MgADP-
-
pH 8.0, 37ºC, at variable MgATP2- concentrations
0.362 - 0.428
MgADP-
-
pH 8.0, 37ºC, at variable adenosine concentrations
0.00019
N1-benzyladenosine
-
-
0.00019
N1-benzyladenosine
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0075
(+)-6-ethyl-6-[4-[(2,6-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.008
(+/-)-6-ethyl-6-[4-[(2,3,5,6-tetrafluorophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.003
(+/-)-6-ethyl-6-[4-[(2,3-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0225
(+/-)-6-ethyl-6-[4-[(2,4-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.01
(+/-)-6-ethyl-6-[4-[(2,4-difluorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.014
(+/-)-6-ethyl-6-[4-[(2,5-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.035
(+/-)-6-ethyl-6-[4-[(2,5-dimethoxyphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.02
(+/-)-6-ethyl-6-[4-[(2,6-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0025
(+/-)-6-ethyl-6-[4-[(2-chloro-4-fluorophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0012
(+/-)-6-ethyl-6-[4-[(2-chloro-4-iodophenyloxy)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.002
(+/-)-6-ethyl-6-[4-[(2-chloro-4-iodophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.001
(+/-)-6-ethyl-6-[4-[(2-chlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.005
(+/-)-6-ethyl-6-[4-[(2-chlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]thiazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0045
(+/-)-6-ethyl-6-[4-[(2-fluorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0035
(+/-)-6-ethyl-6-[4-[(2-imidazolylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.003
(+/-)-6-ethyl-6-[4-[(2-methyl-6-chlorophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.007
(+/-)-6-ethyl-6-[4-[(2-pyrazylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0045
(+/-)-6-ethyl-6-[4-[(2-pyridylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.007
(+/-)-6-ethyl-6-[4-[(2-pyrimidylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.01
(+/-)-6-ethyl-6-[4-[(3,4-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.011
(+/-)-6-ethyl-6-[4-[(3-chloro-4-fluorophenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0035
(+/-)-6-ethyl-6-[4-[(3-chlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.004
(+/-)-6-ethyl-6-[4-[(3-fluorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0125
(+/-)-6-ethyl-6-[4-[(3-methoxyphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0214
(+/-)-6-ethyl-6-[4-[(3-methylphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0032
(+/-)-6-ethyl-6-[4-[(3-trifluoromethoxyphenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo [1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0025
(+/-)-6-ethyl-6-[4-[(3-trifluoromethylphenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.002
(+/-)-6-ethyl-6-[4-[(4-bromophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.015
(+/-)-6-ethyl-6-[4-[(4-ethynylphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.001
(+/-)-6-ethyl-6-[4-[(4-fluorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0025
(+/-)-6-ethyl-6-[4-[(4-iodophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0022
(+/-)-6-ethyl-6-[4-[(4-iodophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]thiazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.014
(+/-)-6-ethyl-6-[4-[(4-methoxyphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0062
(+/-)-6-ethyl-6-[4-[(4-nitrophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0067
(+/-)-6-ethyl-6-[4-[(4-trifluoromethoxyphenylthio)methyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0012
(+/-)-6-ethyl-6-[4-[(phenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.2
(+/-)-6-ethyl-6-[4-[3-(2-diethylaminoethyl)phenoxymethyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.008
(+/-)-6-ethyl-6-[4-[3-(2-hydroxye)thylphenoxymethyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.15
(+/-)-6-ethyl-6-[4-[3-(2-pyrrolidin-1-ylethyl)phenoxymethyl]-phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.01
(+/-)-6-ethyl-6-[4-[[4-[2-(trimethylsilyl)ethynyl]phenylthio]-methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.002
(+/-)-6-ethyl-6-[4-[[4-[2-(trimethylsilyl)ethynyl]phenylthio]-methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]thiazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0044
(+/-)-6-[4-[(2-chlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.009
(+/-)-6-[4-[(3-trifluoromethylphenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.004
(+/-)-6-[4-[(phenylthio)methyl]phenyl]-6,7-dihydrobenzo-[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.04
(-)-6-ethyl-6-[4-[(2,6-dichlorophenylthio)methyl]phenyl]-6,7-dihydrobenzo[b]pyrrolo[1,2-d][1,4]oxazepin-7-one
Homo sapiens
-
at pH 7.5 and 37°C
0.00224
(1R,2R,3S,4R,5S)-4-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.00014
(1R,2R,3S,4R,5S)-4-(4-anilino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.00538
(1R,2S,3R,4R,5S)-1-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(azidomethyl)bicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.00334
(1R,2S,3R,4R,5S)-1-(4-anilino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.000114
(1R,2S,3R,4R,5S)-1-(4-anilino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.00601
(1R,2S,3R,4R,5S)-1-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.000088
(1R,2S,3R,4S,5S)-1-(4-anilino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-methylbicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.00011
(1R,2S,3R,4S,5S)-1-[4-(4-fluoroanilino)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-4-methylbicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.000115
(1R,2S,3R,4S,5S)-1-[4-anilino-5-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-4-methylbicyclo[3.1.0]hexane-2,3-diol
Homo sapiens
37°C, pH not specified in the publication
0.000048
(1S,2R,3S,5R)-3-amino-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
37°C, pH not specified in the publication
0.0088
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol
Mycobacterium tuberculosis
-
pH not specified in the publication, temperature not specified in the publication
0.78
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[4-(1H-imidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]tetrahydrofuran-3,4-diol
Mycobacterium tuberculosis
-
pH not specified in the publication, temperature not specified in the publication
1
10-(dimethylamino)-6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7(6H)-one
Homo sapiens
-
IC50 above 1 mM, at pH 7.5 and 37°C
0.0000012
2-fluoro-4-(benzofuran-2-yl)-7-(beta-d-ribofuranosyl)-7H-pyrrolo-[2,3-d]pyrimidine
Mycobacterium tuberculosis
-
pH not specified in the publication, temperature not specified in the publication
0.005
4-(1H-pyrazol-4-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50 above 0.005 mM, in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0013
4-(furan-2-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.01
4-(furan-3-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50 above 0.01 mM, in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0006
4-amino-5-iodo-7-(4'-C-spirocyclopropyl-beta-D-erythropentofuranosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 600 nM
0.000006
4-amino-5-iodo-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]-pyrimidine
Homo sapiens
-
IC50: 6 nM
0.0000053
4-N-(2-methoxyphenyl)amino-5-(4-ethoxyphenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 5.3 nM
0.000001
4-N-(3,4-ethylenedioxyphenyl)amino-5-(2-methylphenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 1 nM
0.000004
4-N-(3,4-ethylenedioxyphenyl)amino-5-phenyl-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 4 nM
0.000002
4-N-(3-ethoxyphenyl)amino-5-phenyl-7-(beta-D-erythrofuranosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 2 nM
0.000005
4-N-(4-bromophenyl)amino-5-phenyl-7-(beta-D-erythrofuranosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 5 nM
0.000007
4-N-(4-cyanophenyl)amino-5-(4-chlorophenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 7 nM
0.000002
4-N-(4-cyanophenyl)amino-5-(4-ethoxyphenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 2 nM
0.000003
4-N-(4-ethoxyphenyl)amino-5-phenyl-7-(beta-D-erythrofuranosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 3 nM
0.00001
4-N-(4-fluorophenyl)amino-5-(3-aminophenyl)-7-(beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 10 nM
0.0000003
4-N-(4-fluorophenyl)amino-5-phenyl-7-(4'-C-spirocyclopropyl-beta-D-erythro-furanosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 0.3 nM
0.000006
4-N-(4-fluorophenyl)amino-5-phenyl-7-(beta-D-erythrofuranosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 6 nM
0.004
4-N-phenylamino-5-phenyl-7-(5'-deoxy-4'-C-methyl-beta-D-ribo-furanosyl)pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 4000 nM
0.000004
4-N-phenylamino-5-phenyl-7-(beta-D-erythro-furanosyl)-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50: 4 nM
0.00004
5-benzyl-6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.0013
5-fluoro-4-(furan-2-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.01
5-fluoro-4-(furan-3-yl)-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50 above 0.01 mM, in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0011
5-fluoro-7-(beta-D-ribofuranosyl)-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.01
5-fluoro-7-(beta-D-ribofuranosyl)-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50 above 0.01 mM, in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.00082
5-iodo-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
37°C, pH not specified in the publication
0.00009
6,8-bis(anilin-N-yl)-9-(beta-D-ribofuranosyl)purine
Homo sapiens
-
IC50: 90 nM
0.002
6,8-bis(indolin-N-yl)-9-(beta-D-ribofuranosyl)purine
Homo sapiens
-
IC50: 2000 nM
0.0008 - 0.0133
6-(4-[[(2-chlorophenyl)sulfanyl]methyl]phenyl)-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
0.0161 - 0.0204
6-benzylthioinosine
0.15
6-ethyl-6-(3-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7(6H)-one
Homo sapiens
-
at pH 7.5 and 37°C
0.08
6-ethyl-6-(4-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7(6H)-one
Homo sapiens
-
at pH 7.5 and 37°C
0.085
6-ethyl-6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7(6H)-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0012 - 0.0118
6-ethyl-6-[4-[(phenylsulfanyl)methyl]phenyl]-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
0.00048
6-indolin-N-yl-8-chloro-9-(beta-D-ribofuranosyl)purine
Homo sapiens
-
IC50: 480 nM
0.001
6-indolin-N-yl-8-iodo-9-(beta-D-ribofuranosyl)purine
Homo sapiens
-
IC50: 1000 nM
0.00015
6-indolin-N-yl-8-methylthio-9-(beta-D-ribofuranosyl)-purine
Homo sapiens
-
IC50: 150 nM
0.00006
6-indolin-N-yl-8-vinyl-9-(beta-D-ribofuranosyl)purine
Homo sapiens
-
IC50: 60 nM
0.13
6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7(6H)-one
Homo sapiens
-
at pH 7.5 and 37°C
0.1
6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7(6H)-one
Homo sapiens
-
at pH 7.5 and 37°C
0.0012 - 0.061
6-[4-[(2-chloro-4-iodophenoxy)methyl]phenyl]-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
0.0000045
6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]-5-(2-phenylethyl)pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.0000025
6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]-5-(3-phenylpropyl)pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.000038
6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]-5-(4-phenylbutyl)pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.00012
6-[[6-(morpholin-4-yl)pyridin-3-yl]ethynyl]pyrimidin-4-amine hydrate (1:1)
Homo sapiens
pH and temperature not specified in the publication
0.005 - 0.0053
7-(2-naphthyl)-7-deazaadenine
0.0006
7-(3-dibenzo[b,d]furanyl)-7-deazaadenine
Mycobacterium tuberculosis
pH 8.0, 37°C
0.005
7-(beta-D-ribofuranosyl)-4-(1,3-thiazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50 above 0.005 mM, in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.002
7-(beta-D-ribofuranosyl)-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50 above 0.002 mM, in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.01
7-(beta-D-ribofuranosyl)-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
-
IC50 above 0.01 mM, in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0273
7-Deazainosine
Toxoplasma gondii
-
pH 7.5, 37°C
0.001
8-acetylenyl-6-indolin-N-yl-9-(beta-D-ribofuranosyl)-purine
Homo sapiens
-
IC50: 1000 nM
0.0002
8-anilin-N-yl-6-indolin-N-yl-9-(5-deoxy-beta-D-ribofuranosyl)purine
Homo sapiens
-
IC50: 200 nM
0.000019
8-anilin-N-yl-6-indolin-N-yl-9-(beta-D-ribofuranosyl)-purine
Homo sapiens
-
IC50: 19 nM
0.00023
8-ethyl-6-indolin-N-yl-9-(beta-D-ribofuranosyl)purine
Homo sapiens
-
IC50: 230 nM
2900
8-furan-2-yl-6-indolin-N-yl-9-(beta-D-ribofuranosyl)-purine
Homo sapiens
-
IC50: 2900 mM
0.0161
carbocyclic 6-(2,3,4-trimethylbenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0186
carbocyclic 6-(2,4-dichlorobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0136
carbocyclic 6-(2-chloro-6-fluorobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.02
carbocyclic 6-(2-chlorobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0389
carbocyclic 6-(2-fluorobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0197
carbocyclic 6-(2-methylbenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0144
carbocyclic 6-(3,4-dichlorobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0238
carbocyclic 6-(3-methylbenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0197
carbocyclic 6-(3-nitrobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0191
carbocyclic 6-(3-trifluoromethylbenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0183
carbocyclic 6-(4-bromobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0145
carbocyclic 6-(4-chlorobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.049
carbocyclic 6-(4-cyanobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0232
carbocyclic 6-(4-fluorobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0121
carbocyclic 6-(4-methoxybenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0119
carbocyclic 6-(4-methylbenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0146
carbocyclic 6-(4-methylsulfonylbenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0428
carbocyclic 6-(4-nitrobenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.021
carbocyclic 6-(4-trifluoromethoxybenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0128
carbocyclic 6-(p-methoxycarbonylbenzylthio)inosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0191
carbocyclic 6-benzylthioinosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.000037 - 0.0014
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-benzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.00011 - 0.004
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.00032 - 0.0047
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.00063 - 0.002
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thiazolyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.00086 - 0.0024
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.000083 - 0.0037
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.0036 - 0.0039
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.0027 - 0.008
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.00097 - 0.0037
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.00029 - 0.004
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.0018 - 0.0065
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-dibenzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.0031 - 0.025
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-pyrazolyl)-7 H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
0.0294
P1,P5-di(adenosine-5')-pentaphosphate
Trypanosoma brucei
pH and temperature not specified in the publication
0.0059 - 0.0161
pyrimethamine
0.0273 - 0.0412
Sulfadiazine
0.0008
6-(4-[[(2-chlorophenyl)sulfanyl]methyl]phenyl)-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant Q78A, pH 7.5, 37°C
0.001
6-(4-[[(2-chlorophenyl)sulfanyl]methyl]phenyl)-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
wild-type, pH 7.5, 37°C
0.003
6-(4-[[(2-chlorophenyl)sulfanyl]methyl]phenyl)-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant H107A, pH 7.5, 37°C
0.0036
6-(4-[[(2-chlorophenyl)sulfanyl]methyl]phenyl)-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant Q74A, pH 7.5, 37°C
0.0037
6-(4-[[(2-chlorophenyl)sulfanyl]methyl]phenyl)-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant K341A, pH 7.5, 37°C
0.0133
6-(4-[[(2-chlorophenyl)sulfanyl]methyl]phenyl)-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant F338A, pH 7.5, 37°C
0.0161
6-benzylthioinosine
Toxoplasma gondii
-
pH 7.5, 37°C
0.0204
6-benzylthioinosine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0012
6-ethyl-6-[4-[(phenylsulfanyl)methyl]phenyl]-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
wild-type, pH 7.5, 37°C
0.002
6-ethyl-6-[4-[(phenylsulfanyl)methyl]phenyl]-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant Q78A, pH 7.5, 37°C
0.0026
6-ethyl-6-[4-[(phenylsulfanyl)methyl]phenyl]-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant H107A, pH 7.5, 37°C
0.0035
6-ethyl-6-[4-[(phenylsulfanyl)methyl]phenyl]-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant K341A, pH 7.5, 37°C
0.0064
6-ethyl-6-[4-[(phenylsulfanyl)methyl]phenyl]-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant Q74A, pH 7.5, 37°C
0.0118
6-ethyl-6-[4-[(phenylsulfanyl)methyl]phenyl]-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant F338A, pH 7.5, 37°C
0.0012
6-[4-[(2-chloro-4-iodophenoxy)methyl]phenyl]-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
wild-type, pH 7.5, 37°C
0.0023
6-[4-[(2-chloro-4-iodophenoxy)methyl]phenyl]-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant Q78A, pH 7.5, 37°C
0.0033
6-[4-[(2-chloro-4-iodophenoxy)methyl]phenyl]-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant H107A, pH 7.5, 37°C
0.0198
6-[4-[(2-chloro-4-iodophenoxy)methyl]phenyl]-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant K341A, pH 7.5, 37°C
0.0203
6-[4-[(2-chloro-4-iodophenoxy)methyl]phenyl]-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant Q74A, pH 7.5, 37°C
0.061
6-[4-[(2-chloro-4-iodophenoxy)methyl]phenyl]-6-ethyl-6,7-dihydropyrrolo[2,1-d][1,5]benzoxazepine
Homo sapiens
mutant F338A, pH 7.5, 37°C
0.005
7-(2-naphthyl)-7-deazaadenine
Homo sapiens
above 5 micoM, pH 8.0, 37°C
0.0053
7-(2-naphthyl)-7-deazaadenine
Mycobacterium tuberculosis
pH 8.0, 37°C
0.000037
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-benzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0014
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-benzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.00011
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.004
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.00032
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0047
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.00063
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thiazolyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.002
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thiazolyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.00086
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0024
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.000083
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0037
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.0036
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0039
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.0027
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.008
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-furyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.00097
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0037
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.00029
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.004
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(3-thienyl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.0018
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-dibenzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.0065
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-dibenzofuryl)-7H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.0031
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-pyrazolyl)-7 H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Homo sapiens
-
in 50 mM HEPES (pH 6.2), 10 mM KCl, 1 mM MgCl2, temperature not specified in the publication
0.025
cyclo-(3-methylsaligenyl)-beta-D-ribofuranosyl-4-(4-pyrazolyl)-7 H-pyrrolo[2,3-d]pyrimidine-5'-O-phosphate
Mycobacterium tuberculosis
-
IC50 above 0.025 mM, in 50 mM Tris-HCl (pH 8.0), 10 mM KCl, 10 mM MgCl2, temperature not specified in the publication
0.0059
pyrimethamine
Toxoplasma gondii
-
-
0.0161
pyrimethamine
Toxoplasma gondii
-
pH 7.5, 37°C
0.0161
pyrimethamine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0273
Sulfadiazine
Toxoplasma gondii
-
pH 7.5, 37°C
0.0273
Sulfadiazine
Toxoplasma gondii
-
in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2; 1 mM dithiothreitol, 25 mM NaF, at 37°C
0.0412
Sulfadiazine
Toxoplasma gondii
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.